A Single-Arm Phase 2a Study of Pexa-Vec (JX-594) Administered by Weekly Intravenous (IV) Infusions in Patients with Metastatic, Refractory Renal Cell Carcinoma (RCC)

Trial Profile

A Single-Arm Phase 2a Study of Pexa-Vec (JX-594) Administered by Weekly Intravenous (IV) Infusions in Patients with Metastatic, Refractory Renal Cell Carcinoma (RCC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2013

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top